To The Moon

$Amgen(AMGN)$

we’ll take an in-depth look at Amgen (AMGN), covering its recent performance, dividends, and what investors can expect in the future. If you’re considering investing in pharmaceutical stocks, particularly Amgen.

Over the past year, Amgen’s stock has shown mixed performance, with periods of growth followed by pullbacks. Recent upward momentum has been driven by positive earnings and market reactions to its acquisitions. However, factors like FDA approvals, patent expirations, and regulatory news continue to influence its price.

Compared to newer biotech companies experiencing rapid growth, Amgen is seen as a relatively stable player. Its established product portfolio and strong cash flow provide a solid foundation, though its valuation may appear high with a price-to-earnings (P/E) ratio of 37.8, above the sector average.

Did you know that Amgen Inc. is one of the biggest players in the biotech industry? Since its founding in 1980, Amgen has been at the forefront of developing innovative therapies, particularly in areas like oncology, cardiology, and nephrology. The company specializes in biologic treatments that are transforming healthcare.

Amgen’s blockbuster drugs include:

• Neulasta, which helps cancer patients fight infections during chemotherapy.

• Repatha, a groundbreaking cholesterol-reducing medication.

• Otezla, offering new hope to individuals with psoriasis.

These products not only drive Amgen’s revenue but also improve the quality of life for millions worldwide. Amgen operates in over 100 countries, positioning it as a leader in the global pharmaceutical industry. Moreover, its robust pipeline, filled with promising late-stage treatments, indicates a bright future.

Earning Overview

Amgen reported strong financial results for the third quarter of 2024, with total revenues increasing by 23% to $8.5 billion compared to the same period in 2023. This growth was primarily driven by a 24% rise in product sales, attributed to a 29% increase in volume, partially offset by a 2% decrease in net selling price. Excluding contributions from the Horizon Therapeutics acquisition, product sales grew by 8%, driven by a 12% increase in volume.

GAAP earnings per share (EPS) saw a significant increase of 62%, rising from $3.22 to $5.22. This improvement was largely due to mark-to-market gains on Amgen's equity investment in BeiGene, Ltd., higher revenues, and was partially offset by increased operating expenses, including amortization expenses from Horizon-acquired assets.

Fundamental Analysis

Amgen has consistently demonstrated earnings growth, driven by its oncology drugs and cholesterol treatments. The company maintains manageable debt levels and strong free cash flow, enabling it to invest in R&D while returning value to shareholders through dividends and stock buybacks.

Dividends

Amgen is known for its consistent quarterly dividends, offering an attractive yield for income-focused investors. Its reliable dividend history makes it a compelling option for those seeking steady returns. Currently the dividend is around 3.5%

Several key products contributed to the revenue growth:

• Repatha® (evolocumab): Sales increased by 40% year-over-year to $567 million, driven by a 41% increase in volume.

• EVENITY® (romosozumab-aqqg): Sales rose by 30% year-over-year to $399 million, driven by volume growth.

• Prolia® (denosumab): Sales increased by 6% year-over-year to $1.0 billion, driven by a 9% increase in volume.

• BLINCYTO® (blinatumomab): Sales grew by 49% year-over-year to $327 million, primarily driven by volume growth.

• Vectibix® (panitumumab): Sales increased by 12% year-over-year to $282 million, primarily driven by volume growth.

• KYPROLIS® (carfilzomib): Sales rose by 8% year-over-year to $378 million, primarily driven by volume growth outside the U.S.

• LUMAKRAS®/LUMYKRAS™ (sotorasib): Sales increased by 88% year-over-year to $98 million, driven by volume growth and favorable changes to estimated sales deductions.

• XGEVA® (denosumab): Sales grew by 4% year-over-year to $541 million, driven by a higher net selling price.

• Nplate® (romiplostim): Sales increased by 9% year-over-year to $456 million. Excluding U.S. government orders, Nplate sales grew by 18% year-over-year, driven by a 14% increase in volume and a higher net selling price.

• IMDELLTRA™ (tarlatamab-dlle): Generated $36 million in sales during the quarter, with a 200% increase quarter-over-quarter, driven by volume growth.

• MVASI® (bevacizumab-awwb): Sales decreased by 8% year-over-year to $195 million, with expectations of continued sales erosion due to competition.

Guidance

Amgen has made headlines with its massive acquisition of Horizon Therapeutics, one of the largest deals in biotech history. This strategic move strengthens Amgen’s presence in the growing market for autoimmune diseases, potentially unlocking new revenue streams.

In its latest earnings report, Amgen demonstrated solid growth, thanks to sustained demand for its blockbuster drugs. However, like many pharmaceutical companies, Amgen faces challenges such as pricing pressures and regulatory scrutiny, contributing to stock volatility despite strong.

Free Cash Flow

The company generated $3.3 billion in free cash flow during the quarter, up from $2.5 billion in the third quarter of 2023. This increase was driven by business performance and the timing of working capital items, partially offset by lower interest income.

Technical Analysis

Amgen’s stock currently faces resistance between $320 and $330. A breakout above this range could indicate a continued upward trend. The stock remains below its 50-day and 200-day moving averages, suggesting a short-term bearish outlook. However, key support levels around $220 to $230 provide a safety net, and RSI levels indicate room for potential growth.

Risks and Challenges

Patent Expirations and Biosimilar Competition

Biosimilars Threat: Amgen's key products face competition from biosimilars, which can erode market share and reduce pricing power. For instance, products like Enbrel and Neulasta have been under pressure from biosimilar alternatives.

Revenue Decline from Mature Products: As patents expire, Amgen must offset declining sales from older drugs by bringing new products to market.

Key Patent Expirations and Impacts

1. Enbrel (etanercept)

• Uses: Treats autoimmune conditions such as rheumatoid arthritis and psoriasis.

• Patent Status: Enbrel's primary U.S. patents have been upheld in legal battles, protecting the drug until 2029. However, in Europe and other regions, biosimilars have already eroded market share.

• Impact: Enbrel remains a significant revenue driver for Amgen in the U.S., but the rise of biosimilars could present challenges as patents expire.

2. Prolia/Xgeva (denosumab)

• Uses: Prolia is used for osteoporosis; Xgeva treats bone-related cancer conditions.

• Patent Status: The main U.S. patents are set to expire in 2025, with European patents expiring sooner.

• Impact: Denosumab is a blockbuster drug, and its expiration is expected to lead to biosimilar competition, potentially affecting billions in revenue.

3. Neulasta (pegfilgrastim)

• Uses: Stimulates white blood cell production in chemotherapy patients.

• Patent Status: Neulasta has already lost patent exclusivity in the U.S. and other regions, leading to significant revenue erosion due to competition from biosimilars.

• Impact: Biosimilar versions, such as Mylan’s Fulphila, have captured substantial market share, reducing Amgen’s revenues.

4. Epogen (epoetin alfa) and Aranesp (darbepoetin alfa)

• Uses: Treat anemia associated with chronic kidney disease or chemotherapy.

• Patent Status: Both drugs have faced generic and biosimilar competition for years.

• Impact: Revenues from these drugs have steadily declined as more affordable alternatives have entered the market.

5. Sensipar (cinacalcet)

• Uses: Treats secondary hyperparathyroidism in patients with chronic kidney disease.

• Patent Status: Patent exclusivity ended in 2018.

• Impact: Generic competition has nearly eliminated Amgen’s market share for Sensipar.

6. Neupogen (filgrastim)

• Uses: Treats low white blood cell counts.

• Patent Status: Biosimilar competition, including Amgen’s own biosimilar Zarxio, has reduced Neupogen’s revenue over time.

• Impact: Neupogen is no longer a significant revenue driver.

Valuation

Short-Term Traders: Amgen’s stock volatility presents opportunities around earnings reports or regulatory updates. Monitor key price levels and be ready for market reactions.

Long-Term Investors: Focus on Amgen’s stable fundamentals, consistent dividends, and innovative pipeline. While it may lack the explosive growth of newer biotech firms, Amgen’s market position and steady performance make it a strong buy-and-hold candidate.

Slightly Overpriced: Amgen’s valuation metrics are reasonable compared to peers but reflect optimism about its growth prospects and ability to navigate challenges. Risk-Adjusted View: The stock may be overpriced if its pipeline disappoints, biosimilar competition intensifies, or its obesity drug struggles to gain traction. For income-focused investors, the high dividend yield and cash flow stability may justify the current valuation despite growth concerns.

Amgen’s debt levels are elevated but currently manageable due to its strong cash flow, solid credit rating, and strategic debt management. However, rising interest rates, patent expirations, and acquisition-related risks make it essential for the company to deliver on its pipeline and maintain disciplined financial management.

Market sentiment

In the short term, Amgen’s stock may experience volatility due to regulatory news, market sentiment, and quarterly earnings. Long-term growth will depend on its ability to expand in therapeutic areas like oncology and leverage its Horizon Therapeutics acquisition. Its solid dividend yield and strong pipeline make it a promising option for income-focused investors.

Institutional investors hold a significant portion of Amgen's shares, owning approximately 78% of the company. This level of institutional ownership suggests confidence in Amgen's long-term prospects among large investors.

Retail investor sentiment towards Amgen is currently very positive, with 0.5% of TipRanks' retail investors holding AMGN in their portfolios. In the last 30 days, 4.4% of these investors have adjusted their holdings, indicating active interest in the stock.

Conclusion

Analysts project a potential price target of $322 to $383 for Amgen in 2025, with mixed ratings overall. Whether you’re seeking dividend income or exposure to a biotech leader, Amgen represents a solid investment opportunity.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub